177Lu-DOTA-FAPI

N/A

Report date: 2025/11/27 15:48:14

Base Information

Drug Name177Lu-DOTA-FAPI

Drug Alias Name177Lu-DOTA-2P

ClassificationRadiation-emitting products > Nuclides > Lutetium > 177LuRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive therapeutic agent

Mechanisms of ActionRadionuclide imaging enhancersFibroblast activation protein alpha binders

TargetsProlyl endopeptidase FAP

Therapy Area/IndicationsSolid tumoursNeoplasm Metastasis

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaPhase 1 Clinical

Originator CompaniesThe First Affiliated Hospital Of Xiamen University

China Registration ClassN/A

Develop Information

Active CompaniesThe First Affiliated Hospital Of Xiamen University

Inactive CompaniesN/A

Active IndicationsSolid tumoursNeoplasm Metastasis

Inactive IndicationsN/A

Other Information

ATC CodeN/A